The COVID-19 Prevention Network (CoVPN) was formed by the National Institute of Allergy and Infectious Diseases (NIAID) at the US National Institutes of Health to respond to the global pandemic. Using the infectious disease expertise of their existing research networks and global partners, NIAID has directed the networks to address the pressing need for vaccines and monoclonal antibodies (mAbs) against SARS-CoV-2. The CoVPN is comprised of the partners listed below.
The HIV Vaccine Trials Network (HVTN) is the world’s largest publicly funded international collaboration focused on the development of vaccines to prevent HIV/AIDS.
The HIV Prevention Trials Network (HPTN) develops and tests the safety and efficacy of non-vaccine interventions designed to prevent the transmission of HIV.
NIAID established the Infectious Diseases Clinical Research Consortium in 2019. It encompasses the Institute’s long-standing Vaccine and Treatment Evaluation Units (VTEUs) and a new leadership group.
The ACTG established and supports the largest Network of expert clinical and translational investigators and therapeutic clinical trials units in the world. These investigators and units serve as the major resource for HIV/AIDS research on treatment and care for persons living with HIV/AIDS.
Fred Hutchinson Cancer Research Center
1100 Fairview Ave. N.
PO Box 19024
Seattle WA 98109
Monoclonal Antibody (mAb) Studies
359 Blackwell St. Suite 200
Durham, NC 27701
This Network is funded by the National Institute of Allergy and Infectious Diseases, National Institutes of Health.
Selecting the button below will take you to the CoVPN Volunteer Screening Registry.Volunteer Now!